<DOC>
	<DOC>NCT01708590</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy when brodalumab is replaced with placebo in some participants compared with the participants who are still receiving the brodalumab.</brief_summary>
	<brief_title>Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Subject has had stable moderate to severe plaque psoriasis for at least 6 months Subject must be considered, in the opinion of the investigator, to be a suitable candidate for treatment with a biologic per regional labeling Subject has involved body surface area (BSA) ≥ 10%, PASI ≥ 12, and sPGA ≥ 3 at screening and at baseline Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medicationinduced psoriasis, or other skin conditions at (eg, eczema) that would interfere with study evaluations Subject has known history of Crohn's disease Subject has any other significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol Subject has stopped using certain psoriasis therapies as defined in the study protocol Subject has previously used any antiIL17 biologic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>psoriasis, brodalumab (AMG 827)</keyword>
</DOC>